Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background Antidepressant response to a single subanesthetic dose infusion of the glutamatergic modulator ketamine is transient in most depressed patients; however, a minority continue to experience an extended response. This study examined depressive symptoms and potential clinical predictors of extended response to ketamine in subjects with mood disorders. Methods Subjects were diagnosed with either major depressive disorder (MDD) or bipolar depression. All subjects were treatment-resistant and experiencing a major depressive episode of at least moderate severity. MDD subjects were unmedicated and those with bipolar depression were receiving therapeutic-dose lithium or valproate. All subjects received a single 0.5 mg/kg ketamine infusion. Data were collected pre-infusion (baseline) and at days one, 14, and 28 post-infusion. Results Twelve of 93 (12.9%) participants continued to meet response criteria (50% reduction in Montgomery-Asberg Depression Rating Scale (MADRS) score) at two weeks. All depressive symptoms assessed by the MADRS were improved at two weeks in ketamine responders except for sleep duration/depth. A positive family history of alcohol use disorder in a first-degree relative (FHP) and greater dissociation during the infusion were associated with better antidepressant response at two weeks. Improved measures of apparent sadness, reported sadness, inability to feel, and difficulty concentrating at day 1 correlated most strongly with antidepressant effects at two weeks. Limitations Post-hoc design, small sample size, diagnostic heterogeneity. Conclusions: Static (FHP) and dynamic (improved depressive symptoms) factors may be clinically useful in predicting whether a patient will have an extended response to ketamine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“…with antidepressant efficacy in longitudinal MDD and bipolar clinical trials but also included variables previously reported to be associated with ketamine’s antidepressant effects (Niciu et al., 2014c; Niciu et al., 2014d; Obrocea et al., 2002; Permoda-Osip et al., 2014; Trivedi et al., 2006).”
BackgroundCross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Self-citationDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 4×
“Two papers reported the results of a double-blind, placebo-controlled study of a single subanesthetic dose of ketamine in current bipolar depression (“ketamine bipolar”; NCT#00088699, NIH Protocol #04-M-0222, substudy 2) (Diazgranados et al., 2010a; Zarate et al., 2012).”
BackgroundResultInfluentialSelf-citationBDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958 · cited 1×
“Increased slow-wave sleep is considered a biomarker of enhanced synaptic plasticity (Vyazovskiy et al., 2008), which has been implicated in ketamine’s antidepressant mechanism of action (Bjorkholm and Monteggia, 2016; Duncan et al., 2013).”
BackgroundVyazovskiy, V. V., Cirelli, C., Pfister-Genskow, M., Faraguna, U., & Tononi, G. (2008) · Nature Neuroscience · doi:10.1038/nn2035 · Cited by 837 · cited 1×
“Increased slow-wave sleep is considered a biomarker of enhanced synaptic plasticity (Vyazovskiy et al., 2008), which has been implicated in ketamine’s antidepressant mechanism of action (Bjorkholm and Monteggia, 2016; Duncan et al., 2013).”
BackgroundBremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 4×
“Pearson correlations were used to examine associations between percent change in MADRS score at two weeks post-ketamine infusion and the following: (1) the raw values of individual symptoms one day after infusion, and (2) baseline demographic and neuropsychiatric variables and total CADSS score at the end of the 40-mi…”
MethodInfluentialZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 3×
“Two papers reported the results of a double-blind, placebo-controlled study of a single subanesthetic dose of ketamine in current bipolar depression (“ketamine bipolar”; NCT#00088699, NIH Protocol #04-M-0222, substudy 2) (Diazgranados et al., 2010a; Zarate et al., 2012).”
BackgroundResultSelf-citationMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 7×
“Nevertheless, the most promising antidepressant maintenance strategy currently under investigation appears to be repeated-dose ketamine infusions; yet, to date, only a few such studies have been conducted (aan het Rot et al., 2010; Cusin et al., 2016; Diamond et al., 2014; Murrough et al., 2013; Rasmussen et al., 2013…”
BackgroundInfluentialSafety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598 · cited 1×
“However, the antidepressant effects of a single ketamine infusion are transient in most patients (Coyle and Laws, 2015); as an example, only 50% of ketamine responders continue to respond at two days post-infusion (Newport et al., 2015).”
BackgroundDiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564 · cited 4×
“Two papers reported the results of a double-blind, placebo-controlled study of a single subanesthetic dose of ketamine in current bipolar depression (“ketamine bipolar”; NCT#00088699, NIH Protocol #04-M-0222, substudy 2) (Diazgranados et al., 2010a; Zarate et al., 2012).”
BackgroundResultInfluentialSelf-citationNierenberg, A. A., Husain, M. M., Trivedi, M. H., Fava, M., Warden, D., Wisniewski, S. R., Miyahara, S., & Rush, A. J. (2010) · Psychological Medicine · doi:10.1017/s0033291709006011 · Cited by 458
Inescapable versus escapable shock modulates long-term potentiation in the rat hippocampus
Shors, T. J., Seib, T. B., Levine, S., & Thompson, R. F. (1989) · Science · doi:10.1126/science.2704997 · Cited by 458 · cited 1×
“Aberrant glutamatergic neurotransmission has been implicated in both preclinical models of depression and in MDD (Niciu et al., 2014b; Shors et al., 1989).”
Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426
Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309 · cited 5×
“For instance, the glutamatergic modulator riluzole was tested in two randomized, double-blind, placebocontrolled trials but the effect did not separate from placebo (Ibrahim et al., 2012; Mathew et al., 2010).”
BackgroundMethodResultInfluentialSelf-citationDo the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283 · cited 4×
“In addition, while BMI and lack of prior suicide attempt had previously been found to correlate with antidepressant efficacy at earlier time points (Luckenbaugh et al., 2014; Niciu et al., 2014c), these correlations were not replicated in our larger sample at two weeks.”
BackgroundMethodResultInfluentialSelf-citationThe use of ketamine as an antidepressant: a systematic review and meta‐analysis
Coyle, C. M., & Laws, K. R. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2475 · Cited by 279
Duncan, W. C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B. A., Hejazi, N. S., Yuan, P., Brutsche, N., Manji, H. K., Tononi, G., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000545 · Cited by 256 · cited 2×
“Ketamine increased slow-wave sleep activity as well as total sleep time in MDD patients for two days post-ketamine infusion (Duncan et al., 2013), but had little effect on the sleep of bipolar patients taking concurrent mood stabilizers (Duncan and Zarate, 2013).”
BackgroundSelf-citationHaile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., Iqbal, S., Mahoney, J. J., De La Garza, R., Charney, D. S., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001119 · Cited by 253
Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research
Krupitsky, E. M., & Grinenko, A. Y. (1997) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1997.10400185 · Cited by 246
Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F. J., Sanacora, G., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.031 · Cited by 213 · cited 6×
“Haile CN, Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Foulkes A, Iqbal S, Mahoney J.J.r. De La Garza R.n. Charney DS, Newton TF, Mathew SJ. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.”
BackgroundInfluentialSelf-citationIadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201 · cited 1×
“Relatedly, efforts are underway to identify biomarkers of ketamine response (for a review, see (Iadarola et al., 2015)).”
BackgroundSelf-citationClinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., Brutsche, N. E., Nolan, N. M., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08698 · Cited by 165 · cited 7×
“Aberrant glutamatergic neurotransmission has been implicated in both preclinical models of depression and in MDD (Niciu et al., 2014b; Shors et al., 1989).”
BackgroundResultInfluentialSelf-citationMachado-Vieira, R., Yuan, P., Brutsche, N., DiazGranados, N., Luckenbaugh, D., Manji, H. K., & Zarate, C. A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04659 · Cited by 155
Self-citationLee, E. E., Della Selva, M. P., Liu, A., & Himelhoch, S. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.01.003 · Cited by 124
Ketamine as a Potential Treatment for Suicidal Ideation: A Systematic Review of the Literature
Reinstatler, L., & Youssef, N. A. (2015) · Drugs in R&D · doi:10.1007/s40268-015-0081-0 · Cited by 120 · cited 1×
“With the exception of anhedonia (Lally et al., 2014), fatigue (Saligan et al., 2016), and suicidal ideation (DiazGranados et al., 2010b; Reinstatler and Youssef, 2015), the literature looking at specific depressive symptom improvement after ketamine has been limited.”
BackgroundEffect of Baseline Anxious Depression on Initial and Sustained Antidepressant Response to Ketamine
Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J., Richards, E. M., Slonena, E. E., Vande Voort, J. L., Brutsche, N. E., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09049 · Cited by 111
Self-citationNeurobiological phenotypes associated with a family history of alcoholism
Cservenka, A. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.10.021 · Cited by 111
Moaddel, R., Luckenbaugh, D. A., Xie, Y., Villaseñor, A., Brutsche, N. E., Machado-Vieira, R., Ramamoorthy, A., Lorenzo, M. P., Garcia, A., Bernier, M., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3669-0 · Cited by 86 · cited 4×
“Areas of investigation include BDNF (Haile et al., 2014; Laje et al., 2012; Machado-Vieira et al., 2009), Shank3 (Ortiz et al., 2015), D-serine (Moaddel et al., 2015), interleukin-6 (Yang et al., 2015), vascular endothelial growth factor receptor 1 (VEGF-1) (Permoda-Osip et al., 2014), and vitamin…”
BackgroundInfluentialSelf-citationKetamine, Sleep, and Depression: Current Status and New Questions
Duncan, W. C., & Zarate, C. A. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0394-z · Cited by 76 · cited 1×
“Ketamine increased slow-wave sleep activity as well as total sleep time in MDD patients for two days post-ketamine infusion (Duncan et al., 2013), but had little effect on the sleep of bipolar patients taking concurrent mood stabilizers (Duncan and Zarate, 2013).”
BackgroundSelf-citation
Cited by
Alnefeesi, Y., Chen-Li, D., Krane, E., Jawad, M. Y., Rodrigues, N. B., Ceban, F., Di Vincenzo, J. D., Meshkat, S., Ho, R. C. M., Gill, H., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.04.037 · Cited by 186
Mathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.12.023 · Cited by 97
Price, R. B., Kissel, N., Baumeister, A., Rohac, R., Woody, M. L., Ballard, E. D., Zarate, C. A., Deakin, W., Abdallah, C. G., Feder, A., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01757-7 · Cited by 82
“, family history of alcohol use disorder [7, 8]; suicide history [9]; body mass index (BMI) [9]; benzodiazepine use [10]) and mechanistic (e.”
BackgroundSelf-citationThomas, R. K., Baker, G., Lind, J., & Dursun, S. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118793104 · Cited by 69
Hull, T. D., Malgaroli, M., Gazzaley, A., Akiki, T. J., Madan, A., Vando, L., Arden, K., Swain, J., Klotz, M., & Paleos, C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.07.004 · Cited by 58
Metadata
- Authors
- Pennybaker, S. J., Niciu, M. J., Luckenbaugh, D. A., & Zarate, C. A.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 208
- Pages
- 560-566
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W2545381381
- Cited by
- 77
- References
- 32
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.